Rita Veríssimo

Rita Veríssimo

Auto-generated profile, based on publicly available information

Rita Veríssimo

Nephrology Department, Unidade Local de Saúde de Lisboa Ocidental, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
RVRita Veríssimo
Rita Veríssimo
MAManuela Barbosa Almeida
Manuela Barbosa Almeida
JOJoão Pedro Oliveira
João Pedro Oliveira
PPPedro Manuel Reis Pereira
Pedro Manuel Reis Pereira
BRBárbara O. Ribeiro
Bárbara O. Ribeiro
LDLeonidio Dias
Leonidio Dias

1 January 2026 in Case Reports in Transplantation
Verified
Journal Article
Open access
AMAna Cristina Martins
Ana Cristina Martins
GPGonçalo Pimenta
Gonçalo Pimenta
AMAndré Mascarenhas
André Mascarenhas
RVRita Veríssimo
Rita Veríssimo
SQSara Querido
Sara Querido
AWAndre Weigert
Andre Weigert
Hepatitis E virus (HEV) is a common but often underdiagnosed cause of hepatitis in both the general population and transplant patients. Diagnosis is usually made by detecting IgM anti‐HEV antibodies, with immunosuppressed individuals being at higher risk for chronic infection. We present the case of a 56‐year‐old man who developed asymptomatic liver cytolysis 4 months after a kidney transplant, with no significant physical findings or relevant epidemiological history. Abdominal ultrasound revealed hepatic steatosis. Drug‐induced liver injury was suspected, prompting the discontinuation of potential causative agents. However, liver enzymes worsened asymptomatically after 2 weeks, prompting further medication adjustments. Testing for Hepatitis B and C, as well as IgM for Toxoplasma , was negative. Serologies for herpes simplex and varicella zoster were positive for IgG and negative for IgM, and CMV viral load was undetectable. HEV serologies were negative for IgG and IgM. A liver biopsy revealed nonspecific acute hepatitis without fibrosis. The positive HEV plasma viral load was suggestive of Hepatitis E. As the patient was asymptomatic with no further analytical worsening, targeted treatment was not initiated. The patient achieved spontaneous viral clearance in less than 12 weeks, despite his immunocompromised condition. This case report highlights the diagnostic challenges of HEV hepatitis in immunosuppressed patients, as detection may rely solely on viral load testing due to potential serological negativity. This case also highlights that despite the patient′s immunosuppressed condition, viral clearance is possible without the need for targeted antiviral therapy.

31 March 2022 in Portuguese Journal of Nephrology & Hypertension
Verified
Journal Article
Closed access
RVRita Veríssimo
Rita Veríssimo
LSLuís Sousa
Luís Sousa
TCTiago Carvalho
Tiago Carvalho
PFPedro Fidalgo
Pedro Fidalgo
Introduction: Chronic kidney disease has significant morbidity and mortality worldwide. Various studies have demonstrated that incident patients experience a higher mortality rate within the first 3 months of dialysis. Methods: A single-center retrospective case-control study (1:3) was performed to determine early (<90 days) mortality rate and associated risk factors in incident hemodialysis patients from January 2013 to December 2018. We compared variables between survivors and non-survivors at 90 days after initiation of hemodialysis. Multivariate logistic regression was used to calculate the adjusted odds ratio with 95% confidence intervals for the variables associated with early mortality and a predictive model was developed. Results: From a total of 626 incident hemodialysis patients, 48 (7.7%) died before 90 days of treatment. Non-survivors were older [OR 1.07 (1.03-1.11)], had higher rates of non-recovering acute kidney injury [OR 7.91 (3.63- 17.24)], emergency start of hemodialysis [OR 4.31 (2.15-8.62)], congestive heart failure [OR 5.68 (2.81-11.48)], ischemic cardiomyopathy [OR 4.50 (2.25-8.99)], chronic obstructive pulmonary disease [OR 3.60 (1.44-8.95)], Charlson comorbidity index [OR 1.47 (1.27-1.70)] and dependence of assistance in daily living activities [OR 3.46 (1.76-6.82)]. Patients were less likely to have 90-day mortality if they had nephrologist appointments at least 90 days prior to end-stage renal disease [OR 0.25, 95% CI (0.13-0.50); p<0.001] or a higher serum albumin [OR 0.34, 95% CI (0.19-0.62); p<0.001]. Multivariate analysis risk factors independently associated with early mortality were older age [aOR 1.06 (1-01-1.10), p=0.022], acute kidney injury as cause of end-stage renal disease [aOR 12.62 (4.50-35.40), p<0.001], congestive heart failure [aOR 3.79 (1.58-9.11), p=0.003], and Charlson comorbidity index [aOR 1.30 (1.09-1.56), p=0.005]. The model showed very good discriminative ability [AUROC (95% CI) 0.88 (0.83-0.94)]. Conclusion: Early mortality occurred in 7.7% of our population. Our model could be used to identify patients at higher risk of death during the first 90 days of hemodialysis and aid informed decision-making regarding end-stage renal disease treatment options.